{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T02:54:08Z","timestamp":1772765648648,"version":"3.50.1"},"reference-count":25,"publisher":"American Society of Hematology","issue":"18","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,11,3]]},"abstract":"<jats:title\/>\n               <jats:p>Two Letters to Blood address the risks of COVID-19 in populations with precursors of hematological disease. In the first article, Miller and colleagues report on whether clonal hematopoiesis of intermediate potential (CHIP) is associated with adverse outcomes with COVID-19, finding no association between CHIP and 28-day mortality while providing data indirectly linking IL-6 signaling and patient outcomes. In the second article, Ho and colleagues investigate the outcomes of patients with monoclonal gammopathy of undetermined significance (MGUS) with COVID-19, reporting that one-fourth had a severe infection and that on multivariable analysis, adverse outcomes are more likely if immunoparesis is present.<\/jats:p>","DOI":"10.1182\/blood.2022018052","type":"journal-article","created":{"date-parts":[[2022,9,12]],"date-time":"2022-09-12T22:07:45Z","timestamp":1663020465000},"page":"1993-1997","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":21,"title":["Clonal hematopoiesis of indeterminate potential and\u00a0risk of death from COVID-19"],"prefix":"10.1182","volume":"140","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6797-9335","authenticated-orcid":false,"given":"Peter G.","family":"Miller","sequence":"first","affiliation":[{"name":"1Center for Cancer Research and Center for Regenerative Medicine, Massachusetts General Hospital, Boston, MA"},{"name":"2Cancer Program, Broad Institute of Harvard and MIT, Cambridge, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6436-6691","authenticated-orcid":false,"given":"Geoffrey G.","family":"Fell","sequence":"additional","affiliation":[{"name":"3Department of Data Sciences, Dana Farber Cancer Institute, Boston, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brody H.","family":"Foy","sequence":"additional","affiliation":[{"name":"4Department of Pathology & Center for Systems Biology, Massachusetts General Hospital, Boston, MA"},{"name":"5Department of Systems Biology, Harvard Medical School, Boston, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3735-3873","authenticated-orcid":false,"given":"Allison K.","family":"Scherer","sequence":"additional","affiliation":[{"name":"6Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA"},{"name":"7Department of Medicine, Harvard Medical School, Boston, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher J.","family":"Gibson","sequence":"additional","affiliation":[{"name":"8Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9369-4413","authenticated-orcid":false,"given":"Adam S.","family":"Sperling","sequence":"additional","affiliation":[{"name":"2Cancer Program, Broad Institute of Harvard and MIT, Cambridge, MA"},{"name":"8Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA"},{"name":"9Division of Hematology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1114-6964","authenticated-orcid":false,"given":"Bala B.","family":"Burugula","sequence":"additional","affiliation":[{"name":"10Department of Human Genetics, University of Michigan, Ann Arbor, MI"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9979-2682","authenticated-orcid":false,"given":"Tetsushi","family":"Nakao","sequence":"additional","affiliation":[{"name":"2Cancer Program, Broad Institute of Harvard and MIT, Cambridge, MA"},{"name":"8Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA"},{"name":"11Cardiovascular Research Center and Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA"},{"name":"12Division of Cardiology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1846-0411","authenticated-orcid":false,"given":"Md M.","family":"Uddin","sequence":"additional","affiliation":[{"name":"2Cancer Program, Broad Institute of Harvard and MIT, Cambridge, MA"},{"name":"11Cardiovascular Research Center and Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hailey","family":"Warren","sequence":"additional","affiliation":[{"name":"6Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lynn","family":"Bry","sequence":"additional","affiliation":[{"name":"13Department of Pathology, Brigham and Women\u2019s Hospital, Boston, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8376-0344","authenticated-orcid":false,"given":"Olga","family":"Pozdnyakova","sequence":"additional","affiliation":[{"name":"13Department of Pathology, Brigham and Women\u2019s Hospital, Boston, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew J.","family":"Frigault","sequence":"additional","affiliation":[{"name":"1Center for Cancer Research and Center for Regenerative Medicine, Massachusetts General Hospital, Boston, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alex G.","family":"Bick","sequence":"additional","affiliation":[{"name":"14Division of Genetic Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donna","family":"Neuberg","sequence":"additional","affiliation":[{"name":"3Department of Data Sciences, Dana Farber Cancer Institute, Boston, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John M.","family":"Higgins","sequence":"additional","affiliation":[{"name":"4Department of Pathology & Center for Systems Biology, Massachusetts General Hospital, Boston, MA"},{"name":"5Department of Systems Biology, Harvard Medical School, Boston, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8892-8695","authenticated-orcid":false,"given":"Michael K.","family":"Mansour","sequence":"additional","affiliation":[{"name":"6Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA"},{"name":"7Department of Medicine, Harvard Medical School, Boston, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8402-7435","authenticated-orcid":false,"given":"Pradeep","family":"Natarajan","sequence":"additional","affiliation":[{"name":"2Cancer Program, Broad Institute of Harvard and MIT, Cambridge, MA"},{"name":"7Department of Medicine, Harvard Medical School, Boston, MA"},{"name":"11Cardiovascular Research Center and Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8699-2439","authenticated-orcid":false,"given":"Annette S.","family":"Kim","sequence":"additional","affiliation":[{"name":"13Department of Pathology, Brigham and Women\u2019s Hospital, Boston, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6145-882X","authenticated-orcid":false,"given":"Jacob O.","family":"Kitzman","sequence":"additional","affiliation":[{"name":"10Department of Human Genetics, University of Michigan, Ann Arbor, MI"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0197-5451","authenticated-orcid":false,"given":"Benjamin L.","family":"Ebert","sequence":"additional","affiliation":[{"name":"2Cancer Program, Broad Institute of Harvard and MIT, Cambridge, MA"},{"name":"8Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA"},{"name":"15Howard Hughes Medical Institute, Bethesda, MD"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"issue":"1","key":"2022110315271393000_bib1","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1182\/blood-2015-03-631747","article-title":"Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes","volume":"126","author":"Steensma","year":"2015","journal-title":"Blood"},{"issue":"3","key":"2022110315271393000_bib2","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.stem.2017.07.010","article-title":"Therapy-related clonal hematopoiesis in patients with non-hematologic cancers is common and associated with adverse clinical outcomes","volume":"21","author":"Coombs","year":"2017","journal-title":"Cell Stem Cell"},{"issue":"3","key":"2022110315271393000_bib3","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1182\/blood.2021013531","article-title":"Association of clonal hematopoiesis with chronic obstructive pulmonary disease","volume":"139","author":"Miller","year":"2022","journal-title":"Blood"},{"issue":"2","key":"2022110315271393000_bib4","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1161\/CIRCULATIONAHA.119.044362","article-title":"Genetic interleukin 6 signaling deficiency attenuates cardiovascular risk in clonal hematopoiesis","volume":"141","author":"Bick","year":"2020","journal-title":"Circulation"},{"issue":"14","key":"2022110315271393000_bib5","first-page":"1401","article-title":"Clonal hematopoiesis and atherosclerosis","volume":"377","author":"Jaiswal","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"26","key":"2022110315271393000_bib6","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1056\/NEJMoa1409405","article-title":"Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence","volume":"371","author":"Genovese","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"6327","key":"2022110315271393000_bib7","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1126\/science.aag1381","article-title":"Clonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis development in mice","volume":"355","author":"Fuster","year":"2017","journal-title":"Science"},{"issue":"9","key":"2022110315271393000_bib8","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1001\/jamainternmed.2020.3313","article-title":"Is a \u201ccytokine storm\u201d relevant to COVID-19?","volume":"180","author":"Sinha","year":"2020","journal-title":"JAMA Intern Med"},{"issue":"10","key":"2022110315271393000_bib9","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1038\/s41591-020-1051-9","article-title":"An inflammatory cytokine signature predicts COVID-19 severity and survival","volume":"26","author":"Del Valle","year":"2020","journal-title":"Nat Med"},{"issue":"24","key":"2022110315271393000_bib10","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1056\/NEJMoa2028836","article-title":"Efficacy of tocilizumab in\u00a0patients hospitalized with Covid-19","volume":"383","author":"Stone","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"2022110315271393000_bib11","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1007\/s00134-021-06507-x","article-title":"Tocilizumab and remdesivir in hospitalized patients with severe COVID-19 pneumonia: a randomized clinical trial","volume":"47","author":"Rosas","year":"2021","journal-title":"Intensive Care Med"},{"issue":"1","key":"2022110315271393000_bib12","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1001\/jamainternmed.2020.6252","article-title":"Association between early treatment with tocilizumab and mortality among critically ill patients with COVID-19","volume":"181","author":"Gupta","year":"2021","journal-title":"JAMA Intern Med"},{"issue":"1","key":"2022110315271393000_bib13","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1001\/jamainternmed.2020.6820","article-title":"Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: a randomized clinical trial","volume":"181","author":"Hermine","year":"2021","journal-title":"JAMA Intern Med"},{"issue":"1","key":"2022110315271393000_bib14","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1001\/jamainternmed.2020.6615","article-title":"Effect of tocilizumab vs standard care on clinical worsening in patients hospitalized with COVID-19 pneumonia: a randomized clinical trial","volume":"181","author":"Salvarani","year":"2021","journal-title":"JAMA Intern Med"},{"issue":"10285","key":"2022110315271393000_bib15","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1016\/S0140-6736(21)00676-0","article-title":"Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial","volume":"397","author":"Group RC","year":"2021","journal-title":"Lancet"},{"issue":"6","key":"2022110315271393000_bib16","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1038\/s41591-020-0901-9","article-title":"Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19","volume":"26","author":"Liao","year":"2020","journal-title":"Nat Med"},{"issue":"9","key":"2022110315271393000_bib17","doi-asserted-by":"crossref","first-page":"e2022058","DOI":"10.1001\/jamanetworkopen.2020.22058","article-title":"Association of red blood cell\u00a0distribution width with mortality risk in hospitalized adults with SARS-CoV-2 infection","volume":"3","author":"Foy","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"7831","key":"2022110315271393000_bib18","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1038\/s41586-020-2819-2","article-title":"Inherited causes of clonal haematopoiesis in 97,691 whole genomes","volume":"586","author":"Bick","year":"2020","journal-title":"Nature"},{"issue":"14","key":"2022110315271393000_bib19","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1200\/JCO.2016.71.6712","article-title":"Clonal hematopoiesis associated with adverse outcomes after autologous stem-cell transplantation for lymphoma","volume":"35","author":"Gibson","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"2022110315271393000_bib20","article-title":"Cost effective sequencing enables longitudinal profiling of clonal hematopoiesis","author":"Uddin","year":"2, 2022","journal-title":"medRxiv"},{"issue":"26","key":"2022110315271393000_bib21","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1056\/NEJMoa1408617","article-title":"Age-related clonal hematopoiesis associated with adverse outcomes","volume":"371","author":"Jaiswal","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"2022110315271393000_bib22","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1001\/jamacardio.2018.2287","article-title":"Association of interleukin 6 receptor variant with cardiovascular disease effects of interleukin 6 receptor blocking therapy: a phenome-wide association study","volume":"3","author":"Cai","year":"2018","journal-title":"JAMA Cardiol"},{"issue":"14","key":"2022110315271393000_bib23","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1182\/blood.2022015721","article-title":"Clonal hematopoiesis is not significantly associated with COVID-19 disease severity","volume":"140","author":"Zhou","year":"2022","journal-title":"Blood"},{"issue":"1","key":"2022110315271393000_bib24","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.cyto.2014.05.024","article-title":"Interleukin-6 and its receptors: a highly regulated and dynamic system","volume":"70","author":"Wolf","year":"2014","journal-title":"Cytokine"},{"issue":"11","key":"2022110315271393000_bib25","doi-asserted-by":"crossref","first-page":"e658","DOI":"10.1016\/S2665-9913(20)30345-3","article-title":"Genetic variants mimicking therapeutic inhibition of IL-6 receptor signaling and risk of COVID-19","volume":"2","author":"Bovijn","year":"2020","journal-title":"Lancet Rheumatol"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/140\/18\/1993\/1928177\/blood_bld-2022-018052-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/140\/18\/1993\/1928177\/blood_bld-2022-018052-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,3]],"date-time":"2022-11-03T15:27:53Z","timestamp":1667489273000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/140\/18\/1993\/486579\/Clonal-hematopoiesis-of-indeterminate-potential"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,3]]},"references-count":25,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2022,11,3]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2022018052","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,3]]}}}